Qualigen Therapeutics Inc
QLGN.OQ- Latest Trade
- trading higher0.52USD
- Change
- 0
- % Change
0.00%
- Day Range
- -- - --
- 52-Week Range
- 0.45 - 3.12
As of Jul 5 2022. Values delayed up to 15 minutes
- Previous Close
- 0.52
- Open
- 0.00
- Volume
- 0.00
- 3 Month Average Trading Volume
- 24.41
- Shares Out (Mil)
- 35.30
- Market Cap
- 18.42
- Forward P/E
- -0.88
- Dividend Yield
- -99,999.99
Key Statistics
2 mean rating - 1 analysts
- P/E Excl. Extra Items (TTM)
- -99,999.99
- Price To Sales (TTM)
- 4.12
- Price To Book (Quarterly)
- 1.36
- Price To Cash Flow (Per Share TTM)
- -99,999.99
- Total Debt/Total Equity (Quarterly)
- 0.00
- Long Term Debt/Equity (Quarterly)
- 0.00
- Return On Investment (TTM)
- -107.36
- Return On Equity (TTM)
- -76.38
2021 (millions USD)
About Qualigen Therapeutics Inc
Company Information
Qualigen Therapeutics, Inc. is a diversified life sciences company focused on developing treatments for adult and pediatric cancer. The Company's cancer therapeutics pipeline includes QN-302, QN-247 and RAS-F. QN-302 compound is a small molecule genomic quadruplex (G4) selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells. QN-247 is a deoxyribonucleic acid (DNA) coated gold nanoparticle cancer drug candidate to target various types of cancer. RAS-F is a family of rat sarcoma virus (RAS) oncogene protein-protein interaction inhibitor small molecules for preventing mutated RAS genes’ proteins from binding to their effector proteins and preventing this binding to stop tumor growth, especially in RAS-driven tumors such as pancreatic, colorectal and lung cancers. Its pipeline also includes QN-165, a drug candidate for treating COVID-19 and other viral-based infectious diseases.
Address
1880 Century Park E Ste 1000LOS ANGELES, CA
90067-1623
United States
Industry
Biotechnology & Drugs
Executive Leadership
- Michael S. Poirier
- Chairman of the Board, Chief Executive Officer
- Amy Broidrick
- President, Chief Strategy Officer, Director
- Christopher L. Lotz
- Chief Financial Officer, Vice President - Finance
- Shishir Sinha
- Senior Vice President, Chief Operating Officer
- Tariq Arshad
- Senior Vice President, Chief Medical Officer
- Wajdi Abdul-Ahad
- Chief Scientific Officer, Vice President - Research and Development
- Ira E. Ritter
- Director
- Richard A. David
- Independent Director
- Sidney W. Emery
- Independent Director
- Matthew Edward Korenberg
- Independent Director
- Kurt Kruger
- Independent Director
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,805.20 | 0.35%Positive |
| Copper | 663.45 | 1.69%Negative |
| Brent Crude Oil | 111.80 | 1.50%Negative |
| CBOT Soybeans | 1,626.00 | -- |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 3,825.33 | -- |
| Euro STOXX 50 | 3,375.06 | 2.24%Negative |
| FTSE 100 | 7,096.20 | 1.89%Negative |
| Nikkei 225 | 26,423.47 | 1.03%Positive |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes